Gritgen Therapeutics, a leading gene therapy drug developer based in Suzhou, has announced the successful completion of a A-round financing round worth several hundred million yuan. The financing was led by Sequoia China, with participation from Sunlight Insurance, Qingsong Capital, and Beijing Life Science Park Venture Fund. Existing shareholders including China Everbright Limited, Fruitful Harvest, and Huarong Xingyu continued their support in this round.<\/p>\n\n\n\n
Funding Allocation and Company Goals<\/strong> Company Background and Vision<\/strong> Leading Gene Delivery Platform and Pipeline<\/strong>
The proceeds from this round will be primarily directed towards advancing the production, registration, clinical trials, and research of the company’s lead gene therapy products. Additionally, the funds will accelerate the development of other products targeting liver and neurological applications.<\/p>\n\n\n\n
Established in 2019, Gritgen Therapeutics is committed to “standing strong for China and the joy and health of its people.” With a core focus on independent innovation, the company aims to become a globally leading biotechnology company based in China, contributing to global health and well-being.<\/p>\n\n\n\n
Gritgen Therapeutics has developed a globally leading efficient vector platform for liver gene delivery. Its lead product targets the vast and underserved market of hemophilia A, being the first in China to enter the exploratory clinical trial phase. The product has demonstrated promising safety and efficacy data.<\/p>\n\n\n\n